Genmab A/S and Pfizer, Inc. have recently announced that the European Medicines Agency is officially reviewing the marketing authorization application of tisotumab vedotin. This is an antibody-drug conjugate that the two medical companies have developed for the treatment of adult patients who suffer from recurring or metastatic cervical cancer, and who have experienced disease progression post-systemic therapy. The marketing authorization application is backed by data from the innovaTV 301 trial, which was a global, phase 3 randomized trial.
Tisotumab vedotin is an antibody-drug conjugate consisting of Genmab's human monoclonal antibody that targets tissue factor, combined with Pfizer's innovative ADC technology.
Stay updated with more health news by visiting rttnews.com.
